Curated News
By: NewsRamp Editorial Staff
April 28, 2025
BriaCell Therapeutics Announces Pricing of Public Offering
TLDR
- BriaCell Therapeutics announced a public offering of 3,066,666 units at $4.50 per unit for gross proceeds of $13.8 million.
- Each unit includes one common share or pre-funded warrant and one warrant exercisable at $5.25 per share, led by ThinkEquity.
- BriaCell plans to use the net proceeds for working capital, corporate purposes, and advancing business objectives in cancer care.
- InvestorWire is a specialized communications platform focusing on press release syndication for private and public companies.
Impact - Why it Matters
This news matters as it showcases BriaCell Therapeutics' strategic move to raise funds for further development of cancer immunotherapies. Investors and stakeholders can gain insights into the company's financial initiatives and growth plans.
Summary
BriaCell Therapeutics (Nasdaq: BCTX, BCTXZ) (TSX: BCT) announced the pricing of an underwritten public offering of 3,066,666 units at $4.50 per unit for gross proceeds of approximately $13.8 million. The offering, led by ThinkEquity, is expected to close on April 28, 2025. BriaCell plans to use the net proceeds for working capital and advancing business objectives. Learn more here.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, BriaCell Therapeutics Announces Pricing of Public Offering
